Principal Investigator: Professor Dame Lesley Fallowfield
Statistician: Dr Ivonne Solis-Trapala
Funded by: Boehringer Ingelheim GMBH
Progression Free Survival (PFS) is commonly used as an endpoint in clinical trials of novel cancer therapies. The aim of this study is to find out what this means for patients. What they understand about and expect from these treatments and if the benefits from the treatment controlling the cancer make it worth any side effects they could or do experience.